Patents Assigned to Inserm
  • AAV vectors for in vivo gene therapy of rheumatoid arthritis
    Publication number: 20070104687
    Abstract: The present invention relates to the field of adeno-associated virus (AAV) based gene therapy, in particular in vivo gene therapy, of rheumatoid arthritis (RA). The invention provides recombinant AAV virions being highly efficient in delivering genes encoding therapeutic proteins to the arthritic joints, and method for using such virions in in vivo gene therapy.
    Type: Application
    Filed: September 1, 2004
    Publication date: May 10, 2007
    Applicants: Academisch Medisch Centrum, Institut National De La Sante ET DE LA Recherche Medicale (Inserm)
    Inventors: Paul Tak, Christian Jorgensen
  • Method for detecting leptin receptor ligands
    Patent number: 7211399
    Abstract: The present invention relates to a method for detecting leptin receptor ligands using resonance energy transfer between fusion proteins comprising a leptin receptor and energy donor protein and a leptin receptor and energy acceptor protein. The present invention also relates to the fusion proteins for implementing said method.
    Type: Grant
    Filed: February 25, 2003
    Date of Patent: May 1, 2007
    Assignees: Aventis Pharma S.A., CNRS, INSERM
    Inventors: Ralf Jockers, Cyril Couturier
  • Polypeptide derived from gp41, a vaccine composition comprising said polypeptide, and uses for treating an infection by an hiv virus in an individual
    Publication number: 20070092525
    Abstract: The present invention relates to the field of the in vitro diagnosis of the progression status of an infection of an individual with a virus belonging to the family of the Human Immunodeficiency Viruses (HIV) as well as with the therapeutical treatment of this infectious disease. The invention also relates to immunological compounds and vaccine compositions comprising a polypeptide derived from gp41.
    Type: Application
    Filed: February 7, 2005
    Publication date: April 26, 2007
    Applicants: Institut National de la Sante et de la Recherche Medicale (INSERM), Assistance Publique Hopitaux de Paris
    Inventors: Vincent Vieillard, Patrice Debre
  • Type B botulism toxin inhibitors
    Patent number: 7205435
    Abstract: Novel compounds of general formula (I), are provided with inhibitory properties for the type B botulism toxin activity, along with methods for preparation thereof and corresponding pharmaceutical compositions.
    Type: Grant
    Filed: April 10, 2002
    Date of Patent: April 17, 2007
    Assignees: Institut National de la Sante et de la Recherche Medicale (INSERM), Centre National de la Recherche Scientifique (C.N.R.C.)
    Inventors: Bernard Roques, Christine Anne, Serge Turcaud, Marie-Claude Fournie-Zaluski
  • Infectious pestivirus pseudo-particles containing functional Erns, E1, E2 envelope proteins
    Patent number: 7198935
    Abstract: The invention relates to the generation and the use of pestivirus pseudo-particles containing native functional E1, E2 envelope glycoproteins assembled onto retroviral core particles. These particles are highly infectious and constitute a valid model of pestivirus virion.
    Type: Grant
    Filed: March 3, 2004
    Date of Patent: April 3, 2007
    Assignee: Institut National de la Sante et de la Recherche Medicale (INSERM)
    Inventors: Birke Bartosch, Francois-Loic Cosset
  • ICBP90 polypeptide and its fragments and polynucleotides coding for said polypeptides and applications for diagnosing and treating cancer
    Patent number: 7199218
    Abstract: The invention concerns a novel ICBP90 (Inverted CCAAT box binding protein 90) and its fragments, polynucleotides coding for said polypeptides and specific antibodies directed against said polypeptides. The invention also concerns methods and kits for diagnosing cell proliferation and compounds useful as medicine for preventing and/or treating pathology involving cell proliferation and in particular cancer.
    Type: Grant
    Filed: June 22, 2000
    Date of Patent: April 3, 2007
    Assignee: Institut National de la Sante et de la Recherche Medicale :(INSERM)
    Inventors: Christian Bronner, Raphaël Hopfner, Marc Mousli, Jean-Marc Jeltsch, Yves Lutz, Pierre Oudet
  • S-adenosyl methionine decarboxylase inhibition for the treatment of a herpes simplex virus infection
    Publication number: 20070059299
    Abstract: The present invention relates to pharmaceutical compositions for the treatment of herpes simplex virus infections, including HSV-1 and HSV-2 infections, including an inhibitor of S-adenosyl methionine decarboxylase in combination with another agent for treating such infections, such as acyclovir, in an acceptable carrier.
    Type: Application
    Filed: October 9, 2003
    Publication date: March 15, 2007
    Applicant: Institut National de la Sante et de la Recherche Medicale (INSERM)
    Inventors: Jean-Jacques Diaz, Anna Greco
  • Keratinocytes obtained from embryonic stem cells of mammals
    Patent number: 7186558
    Abstract: The present invention relates to a method for inducing the differentiation of mammals' embryonic stem cells into keratinocytes, comprising the following steps of: isolating an extracellular matrix secreted by at least one mammals' cell type, cultivating mammals' embryonic stem cells in parallel in an undifferentiated condition in an appropriate culture medium in the presence of LIF, seeding the embryonic stem cells as a monolayer on said extracellular matrix, cultivating the thus seeded embryonic stem cells in the absence of LIF for a period of time sufficient for their differentiation into keratinocytes, and collecting the thus obtained keratinocytes.
    Type: Grant
    Filed: May 30, 2002
    Date of Patent: March 6, 2007
    Assignee: INSERM
    Inventors: Daniel Aberdam, Christelle Coraux
  • Use of ULIP proteins in the diagnosis and therapy of cancers and paraneoplastic neurological syndromes
    Patent number: 7183400
    Abstract: The invention concerns a purified polypeptide, biologically active polypeptide derivative or fragment of said purified polypeptide, comprising an amino acid sequence selected among SEQ.ID. No. 2, No. 4, No. 6 and No. 8.
    Type: Grant
    Filed: February 19, 1998
    Date of Patent: February 27, 2007
    Assignee: Institut National de la Sante et de la Recherche Medicale (INSERM)
    Inventors: Michèle Aguera, Marie-Françoise Belin, Jérôme Honnorat, Pappachan Kolattukudy, ThanhTam Quach, Tamara Byk, André Sobel, Dominique Aunis, Jean-Christophe Antoine
  • Method for demonstration of a molecular event in a cell by means of fluorescent marker proteins
    Publication number: 20070042445
    Abstract: The invention relates to a method for demonstration of the occurrence of a molecular event, particularly in a cell, characterised by the detection of the “solubilisation” of a fixed protein marker (or the fixing of a solubilised protein marker) which is a direct or indirect marker for the occurrence of the particular molecular event. Said protein marker is present in the cell before the above detection, the cell being subjected to a permeabilisation of the plasma membrane before detection, which liberates the solubilised protein into the extracellular medium, the presence of the marker protein thus being detected in the cell or the extracellular medium by any appropriate means, which permits the detection of whether the solubilisation, or the fixing have taken place and, hence, the corresponding molecular event.
    Type: Application
    Filed: June 30, 2004
    Publication date: February 22, 2007
    Applicant: Institut National de la Sante et de la Recherche Medicale (INSERM)
    Inventors: Francois Ichas, Francesca De Giorgi Ichas, Pier-Vincenzo Piazza, Jean Dessolin, Laura Schembri, Flora Tomasello, Lydia Lartigue
  • Use of hepcidin as a regulator of iron homeostasis
    Patent number: 7169758
    Abstract: The invention concerns the use of hepcidin for the diagnosis and therapy of disorders of iron homeostasis. Hepcidin can be used in the treatment of disorders resulting from iron overload, while inhibitors of hepcidin can he used in the treatment of anaemia.
    Type: Grant
    Filed: May 24, 2002
    Date of Patent: January 30, 2007
    Assignee: Institut National de la Sante et de la Recherche Medicale (Inserm)
    Inventors: Gaël Nicolas, Sophie Vaulont, Axel Kahn
  • Fluorescence detection of proteases or peptidases
    Patent number: 7169574
    Abstract: The invention concerns the use of a PyA-(Z)x-pNF group in a substrate for detecting, identifying and/or analyzing by fluorometry peptidases or proteases capable of cleaving the or a bond between a PyA and pNF and/or compounds with inhibiting or activating activity with respect to enzymes capable of cleaving said bond.
    Type: Grant
    Filed: April 6, 2001
    Date of Patent: January 30, 2007
    Assignees: Institut National de la Sante et de la Recherche Medicale (INSERM), Centre National de la Recherche Scientifique (C.N.R.S.)
    Inventors: Bernard Pierre Roques, Nathalie Luciani, Marie-Claude Fournie-Zaluski, Hugues de Rocquigny
  • Peptide substrate identified by type BoNT/B botulinus toxin and use thereof for assaying and/or detecting said toxin or corresponding inhibitors
    Patent number: 7160982
    Abstract: A peptide substrate is identified by type BoNT/B botulinus toxin, characterized in that it incorporates in its structure a fragment of formula PYA-(Z)-pNF, wherein Z represents one or several amino acids, said fragment being cleavable by said toxin.
    Type: Grant
    Filed: May 31, 2001
    Date of Patent: January 9, 2007
    Assignee: Institut National de la Sante et de la Recherche Medicale (Inserm)
    Inventors: Bernard Roques, Christine Anne
  • Gene involved in CADASIL, method of diagnosis and therapeutic application
    Patent number: 7138234
    Abstract: The invention concerns the Notch3 gene and the corresponding protein, which are involved in CADASIL. The invention concerns, in particular, methods for demonstrating mutations in this gene, which are linked to the risk of developing CADASIL and related diseases.
    Type: Grant
    Filed: February 3, 2003
    Date of Patent: November 21, 2006
    Assignees: Institut National de la Sante et de la Recherche Medicale (INSERM), Assistance Publique-Hopitaux de Paris
    Inventors: Elisabeth Tournier-Lasserve, Anne Joutel, Marie-Germaine Bousser, Jean-François Bach
  • Bifunctional chelating agent
    Patent number: 7132513
    Abstract: The invention concerns a ligand comprising wherein n is an integer from 1 to 5, X represents —NO2, —NH2, —NCS, —NHCOCH2-Z. NHCO—W—COCNHS, —NH-Q, —NHCS-Q, —NHCOCH2-Q, or —NHCO(CH2)m ?-Q where Q is an hapten chosen from the group consisting of steroids, enzymes, proteins, monoclonal antibodies, chimeric antibodies, or fragments thereof or any activated linker ready for coupling reaction, Y is CO2H or PO3H2 W is —(CH2)m— m is an integer from 1 to 10.
    Type: Grant
    Filed: March 9, 2001
    Date of Patent: November 7, 2006
    Assignees: European Community, INSERM Insitut National de la Santé et de la Recherche Médicale
    Inventors: Ali Ouadi, Jean-François Gestin, Christos Apostolidis
  • Method and device for the mapping of intraretinal ph and device for the photocoagulation of peripheral retinal areas
    Publication number: 20060241362
    Abstract: The invention relates to a method of mapping the intraretinal pH of a retina which is marked by a pH-dependent fluorescent marker, in which the retina is illuminated with a first excitation radiation. According to the invention, a first image of the fluorescence emitted by the retina is formed as a bi-directional matrix of pixels at the wavelength of the peak of the fluorescence emission spectrum. Subsequently, the retina is illuminated with a second excitation radiation and a second image is formed of the fluorescence emitted thereby. Finally, the ratio at each pixel between the levels of fluorescence emitted in response to the two respective wavelengths is calculated, said ratio being representative of the pH of the retina, and a pH map of the retina is deduced.
    Type: Application
    Filed: March 5, 2004
    Publication date: October 26, 2006
    Applicant: Institut National de la Sante et de la Recherche Medicale (INSERM)
    Inventors: Serge Mordon, Philippe Rochon
  • Novel derivatives of 4,4' dithiobis-(3-aminobutane-1-1-sulfonates) and compositions comprising the same
    Publication number: 20060205695
    Abstract: The invention relates to derivatives of 4,4?-dithiobis-(3-aminobutane-1-sulfonates) of formula (1), of use for the treatment and prevention of primary and secondary arterial hypertension.
    Type: Application
    Filed: August 6, 2004
    Publication date: September 14, 2006
    Applicant: Institut Natinal de la Sante et de la Rechereche (Inserm)
    Inventors: Bernard Roques, Nicolas Inguimbert, Marie-Claude Fournie-Zaluski, Pierre Corvol, Catherine Llorens-Cortes
  • Method for the treatment of diseases linked to an accumulation of triglycerides and cholesterol
    Publication number: 20060167098
    Abstract: The present invention concerns a method for the treatment and/or the prevention of diseases linked to the accumulation of triglycerides in tissues and blood comprising at least the step of administering to a human or non human animal in need thereof, as therapeutically active agent, an effective amount of (3-aminoisobutyric acid, derivative, prodrug, metabolite or complex thereof.
    Type: Application
    Filed: April 15, 2004
    Publication date: July 27, 2006
    Applicant: Institut National De La Sante ET De LA Recherche Medicale (Inserm)
    Inventor: Bernard Fromenty
  • Novel derivatives of 4,4'-dithiobis-(3-aminobutane-1-sulfphonates) and compositions containing same
    Publication number: 20060135602
    Abstract: The invention relates to the bis-hydrochloride of 4,4?-dithiobis-(3-aminobutane-1-sodium sulphonate) and the bis-trifluoracetate of 4,4?-dithiobis-(3-aminobutane-1-sulphonate of 2,2-dimethylpropyl). The invention also relates to a pharmaceutical composition comprising one of said compounds and to the use of one of said compounds for the production of a medicament. The invention is suitable for use in a treatment method for hypertension and indirectly- or directly-linked illnesses.
    Type: Application
    Filed: July 16, 2003
    Publication date: June 22, 2006
    Applicant: Institut National De La Sante Et De La Recherche Medicale (INSERM)
    Inventors: Marie-Claude Fournie-Zaluski, Catherine Llorens-Cortes, Bernard Roques, Pierre Corvol
  • Quinoline derivatives process of synthesis and medicaments containing these derivatives
    Patent number: 7064133
    Abstract: The invention relates to derivatives corresponding to formula I: in which X is an alkyl-(CH2)n— chain with n=0, 1 or 2, or O or N, Z is an aromatic which may contain heteroatoms chosen from O, N or S, as substitutions for the carbon atoms constituting said aromatic ring, this ring being substituted or otherwise with Rb, Rb represents 1 to 3 substituents chosen from —OH, —OR, —COOH, —COOR, —COH, —COR, —NH2, —NH(R), —NH(R,R?), —SH, —SR and CN, Ra is H or —(CH2)n?—Y, with n?=0, 1, 2 or 3 and Y and —CH3, —COOH, —COOR, —CN, —OH, —OR, SR, or an aryl group optionally substituted with Rb, R and R? represent a linear or branched alkyl chain of 1 to 4 C, and their pharmaceutically acceptable salts. Application as active ingredient of medicaments inhibiting retrovirus integrases.
    Type: Grant
    Filed: October 14, 2002
    Date of Patent: June 20, 2006
    Assignees: Bioalliance Pharma, Universite Paris SUD (Paris XI), Institut National de la Sante et de la Recherche Medicale (INSERM), Institut Gustave Roussy
    Inventors: Jean D'Angelo, Christophe Benard, Michele Danet, Marc Le Bret, Jean-Francois Mouscadet, Fatima Zouhiri, Marie Bayle, Didier Desmaele, Laurence Jeanson, Herve Leh, Frederic Subra